Product
IPI-549
Aliases
IPI-549 (eganelisib)
4 clinical trials
14 indications
Indication
Bladder CancerIndication
Solid TumorIndication
Advanced CancerIndication
Breast CancerIndication
Renal Cell CarcinomaIndication
Triple-Negative Breast CancerIndication
Ovarian CancerIndication
Head and Neck Squamous Cell CarcinomaIndication
Head and Neck CancerIndication
Head and Neck CarcinomaIndication
Head and Neck Cancer Stage IVIndication
Human Papillomavirus-Related CarcinomaIndication
HPV-related malignancyIndication
HPV-Related Squamous Cell CarcinomaClinical trial
A Phase 2, Multicenter, Randomized, Double-Blind, Active-Control Study to Evaluate the Efficacy and Safety of Nivolumab Administered in Combination With IPI-549 Compared to Nivolumab Monotherapy in the Treatment of Patients With Immune Therapy-Naïve, Advanced Urothelial CarcinomaStatus: Completed, Estimated PCD: 2020-11-30
Clinical trial
Ph 2, Multi-arm, Multicenter, Open-label Study to Evaluate Efficacy and Safety of IPI-549 Administered in Combo With Front-line Treatment Regimens in Pts With Locally Advanced and/or Metastatic Triple-Negative Breast Cancer or Renal Cell CarcinomaStatus: Active (not recruiting), Estimated PCD: 2023-08-31
Clinical trial
A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Breast or Gynecologic MalignanciesStatus: Completed, Estimated PCD: 2021-07-01
Clinical trial
Phase 2 Window of Opportunity Study of IPI-549 in Patients With Locally Advanced HPV+ and HPV- Head and Neck Squamous Cell CarcinomaStatus: Recruiting, Estimated PCD: 2023-06-01